AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06490614
Drug: Nalbuphine in superficial cervical plexus block
DrugBank: Nalbuphine (DB00844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: While the patient is in the supine position, the head will be turned to the opposite side of the surgical incision, and a line extending from the mastoid process to the clavicular head of the sternomastoid muscle will be marked. Aseptic preparation of this area will be done, and then the block needle will be inserted at the midpoint of this line with injection of bupivacaine 0.25%, 10 mg of Nalbuphine (nalufin 20mg/ml), and adrenaline 1:200,000 in a total volume of 10ml normal saline in the above, below, and middle directions subcutaneously, creating a sausage-shaped swelling. The sensory block will be assessed with ice chips in the dermatome corresponding to the block, which included the skin of the neck, upper chest, shoulder, and ear, until the completion of the sensory blockade.
Trial: NCT06385561
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol is administered orally twice daily in a dosage of 100 mg (daily total of 200 mg)
Trial: NCT06337253
Drug: Sulfadoxine/pyrimethamine plus amodiaquine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Seasonal Malaria Chemoprevention with SPAQ has not been trialed or introduced in Malawi yet. This intervention trial is different from others because of the location and because, traditionally, a full round of SMC with SPAQ that involves between 3-5 cycles is administered. Our trial is the first one that will only distribute one cycle of SMC with SPAQ. The data collected during the 42 days after SMC distribution will be used to estimate the medicines chemoprevention effectiveness at preventing malaria in children aged 3-59 months. This data, together with the resistance markers data will then be fed into a dynamical model that collaborators at Imperial College London have developed that will predic the potential impact of upscaling SMC in similar geographies.
Trial: NCT05827835
Drug: CD7 CAR-T cells injection
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD7 CAR T cells treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
Trial: NCT04525235
Drug: rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of a cocktail of phenotyping probe drugs (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam and digoxin) will be administered together with standard dose rifampicin and 40 mg/kg rifampicin, respectively. Blood samples will be taken to assess phenotyping metrics of the cocktail agents and rifampicin pharmacokinetic parameters. The effect of high and standard dose rifampicin on the phenotyping metrics of the cocktail agents will be compared by using the bioequivalence approach
Trial: NCT06746311
Drug: HT-101
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of HT-101 administered subcutaneously.
Trial: NCT06746311
Drug: HT-101
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose of HT-101 administered subcutaneously.
Trial: NCT05967052
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin pharmacotherapy
Trial: NCT02826837
Drug: LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The subjects will be administered FOLFOX + Bevacizumab/Cetuximab by intravenous infusion.~Cycles repeat every 2 weeks. Dose and schedule modifications may be made at the treating physician's discretion.~A standard 3+3 trial design will be used for LEAC-102 dose escalation cohorts.The dosing of LEAC-102 will be divided into 3 cohorts, the subjects will receive LEAC-102 every day~Cohort 1: LEAC-102 500 mg capsule, 3 capsules, three times per day for 24 weeks (oral), Cohort 2: LEAC-102 500 mg capsule, 4 capsules, three times per day for 24 weeks (oral), Cohort 3: LEAC-102 500 mg capsule, 5 capsules, three times per day for 24 weeks (oral)
Trial: NCT06086613
Drug: AGA2115
RxNorm normalized name: AGA2115
DrugBank: AGA2115 (DB17840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part A, participants will receive AGA2115 as a single dose administered as a subcutaneous (SC) injection (5 cohorts) or as an intravenous (IV) infusion (1 cohort).~In Part B, participants will receive AGA2115 in multiple doses administered as a SC injection.
Trial: NCT05316883
Drug: Clozapine
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clinical doses adjusted to sideeffects and clinical effect
Trial: NCT06504420
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive Sirolimus 1.5mg/d for 48 weeks in addition to their ongoing APS treatment regimen
Trial: NCT06024889
Drug: Furosemide Injection
RxNorm normalized name: furosemide Injection
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 80 mg furosemide is followed by assessing blood pressure, peripheral oxygen saturation, pulmonary fluid content by ReDS\*, and ultrasound examination of heart and lungs, including assessment of filling pressures with doppler and strain analysis. These measurements are repeated at multiple time points until 6 hours have elapsed.
Trial: NCT04938323
Drug: BCG Vaccine
RxNorm normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: .1 mL of reconstituted BCG vaccine given intradermally at baseline.
Trial: NCT06213935
Drug: Midodrine
RxNorm normalized name: Midodrine
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg tablets of midodrine 1 hour before spinal anesthesia to prevent post spinal anesthesia hypotension
Trial: NCT04051801
Drug: Dose Escalation of VU319
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose levels of the cohorts will be increased step wise
Trial: NCT05626439
Drug: Staccato alprazolam
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study participants will receive single dose of Staccato alprazolam by inhalation at pre-specified time points.
Trial: NCT05626439
Drug: Oral alprazolam
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study participants will receive single dose of oral alprazolam at pre-specified time points.
Trial: NCT06128070
Drug: Ruxolitinib Phosphate
RxNorm normalized name: Ruxolitinib Phosphate
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06128070
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05321511
Drug: Triptorelin acetate (a-GnRH)
RxNorm normalized name: triptorelin acetate
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adminsitration of triptoreline acetate 0.2 mg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
Trial: NCT04849065
Drug: MNC (Mononuclear cells)
RxNorm normalized name: Human umbilical cord blood mononuclear cell-conditioned medium
DrugBank: Human umbilical cord blood mononuclear cell-conditioned medium (DB15724)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Intramuscular infusion of autologous BM CMN into the TA muscle of one of the lower limbs (experimental side)~* Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)
Trial: NCT03184155
Drug: Nicardipine
RxNorm normalized name: Nicardipine
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mcg intracoronary nicardipine injection prior to PCI followed by an additional 2-4 doses of 100 mcg intracoronary nicardipine depending on complexity of PCI
Trial: NCT04843423
Drug: Cariprazine
RxNorm normalized name: Cariprazine
DrugBank: Cariprazine (DB06016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At the screening visit, those who are eligible will enter an open-label trial with cariprazine in doses ranging from 1.5mg to 3 mg. The study will begin with a single week of cariprazine 1.5 mg oral tablets. After the first week the participants' dosage may be increased up to a maximum of 3 mg daily. This dose will remain fixed after 4 weeks of treatment until week 8, at which time the medication will be discontinued.~Because the drug is not yet available to market in Canada, participants will be dispensed the drug in appropriately labelled 7-day tablet containers with the appropriate dose, including 3 additional tablets to account for scheduling conflicts. Participants will be instructed to return the tablet containers at each Study Visit in order to assess drug compliance. They will then be newly dispensed the appropriate quantity according to their next scheduled study visit.
Trial: NCT06194032
Drug: Baxdrostat
RxNorm normalized name: Baxdrostat
DrugBank: Baxdrostat (DB19090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive baxdrostat as two separate doses.
Trial: NCT06194032
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose moxifloxacin
Trial: NCT05496335
Drug: BOTOX
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Intramuscular Injection
Trial: NCT00000723
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000723
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04906083
Drug: Avatrombopag
RxNorm normalized name: AVATROMBOPAG
DrugBank: Avatrombopag (DB11995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Avatrombopag:~PLT：30\~50×10\^9/L patients, 40 mg/d; PLT：\<30×10\^9/L patients, 60 mg/d.
Trial: NCT04376762
Drug: Fibrinogen
RxNorm normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen Concentrate (Human) Injection \[Fibryga\] (dose: 70 mg/kg; intervention group). in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF \< 10 mm on the FIBTEM assay of ROTEM).
Trial: NCT00082316
Drug: Capsaicin Dermal Patch
RxNorm normalized name: capsaicin Medicated Patch
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05491330
Drug: Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose)
RxNorm normalized name: NIRMATRELVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
Trial: NCT05491330
Drug: Nirmatrelvir 150 mg + Ritonavir 100 mg (test)
RxNorm normalized name: NIRMATRELVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
Trial: NCT05491330
Drug: Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose)
RxNorm normalized name: NIRMATRELVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
Trial: NCT05217719
Drug: recombinant human thrombopoietin
RxNorm normalized name: Recombinant Human Thrombopoietin
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of rhTPO is 15,000 U per day. The subcutaneous injection will be terminated when PCs are increased to normal. The duration of rhTPO will be 7 days.
Trial: NCT06370130
Drug: Esketamine 0.2mg/kg
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received 0.2 mg/kg of esketamine intravenously for 30 s，after 120 s of propofol and disappearance of the eyelash reflex, a laryngeal mask was inserted.~The test was performed using the sequential method. The initial dose of propofol was 2 mg/kg, which can be easily inserted into the LMA, and the propofol dose ratio of the adjacent patient was 0.9. If there was a positive reaction to the LMA insertion, the gradient was increased for the next patient; otherwise, the gradient was decreased, and the study was terminated after seven crossover inflection points.
Trial: NCT06370130
Drug: Esketamine 0.3mg/kg
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received 0.3 mg/kg of esketamine intravenously for 30 s，after 120 s of propofol and disappearance of the eyelash reflex, a laryngeal mask was inserted.~The test was performed using the sequential method. The initial dose of propofol was 2 mg/kg, which can be easily inserted into the LMA, and the propofol dose ratio of the adjacent patient was 0.9. If there was a positive reaction to the LMA insertion, the gradient was increased for the next patient; otherwise, the gradient was decreased, and the study was terminated after seven crossover inflection points.
Trial: NCT00309725
Drug: galantamine
RxNorm normalized name: Galantamine
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05291039
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: group 1 (n=20): patients will receive IFX
Trial: NCT05291039
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: group 2 (n=20): patients will receive ADA
Trial: NCT06483139
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
Trial: NCT06168786
Drug: Fruquintinib
RxNorm normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib:5mg ,qd,po, d1-d14, q3w
Trial: NCT06168786
Drug: Cadonilimab
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab:10mg/kg, ivgtt, d1, q3w
Trial: NCT00000718
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000718
Drug: Zalcitabine
RxNorm normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04715932
Drug: Hesperidin
RxNorm normalized name: Hesperidin
DrugBank: Hesperidin (DB04703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
Trial: NCT05219084
Drug: hip denervation
RxNorm normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% 2ml was injected into each genicular nerve
Trial: NCT00440960
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00440960
Drug: midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00440960
Drug: alfentanil
RxNorm normalized name: Alfentanil
DrugBank: Alfentanil (DB00802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00440960
Drug: lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04689919
Drug: Rivaroxaban 20 MG Oral Tablet
RxNorm normalized name: rivaroxaban 20 MG Oral Tablet
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The subjects randomly received single oral dose of Rivaroxaban 20 MG Tablet.
Trial: NCT05939635
Drug: IV morphine patient-controlled analgesia (PCA)
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine will be administered via PCA device for the first 24 hours after surgery
Trial: NCT00006199
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00476983
Drug: saquinavir/ritonavir plus truvada
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SQV/r 1500/100 mg OD + Truvada OD for 2 years
Trial: NCT04923776
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dosage for this drug is area under the curve (AUC) 5 mg/ml/min intravenous, Day 1, every 21 days for 4 cycles. This is standard of care.
Trial: NCT04923776
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dosage for this drug is 100 mg/m2 Intravenous, Days 1-3, every 21 days for 4 cycles. This is standard of care.
Trial: NCT04923776
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dosage for this drug is 1200 mg Intravenous, Day 1, every 21 days until disease progression. This is standard of care.
Trial: NCT05943821
Drug: Allopurinol 200 mg
RxNorm normalized name: allopurinol 200 MG
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention will occur after randomly allocating participants to the first group (G1), in which patients will receive allopurinol at an initial daily dose of 200 mg, or to the second group (G2), where they will receive a placebo. The placebo will be prepared as tablets with the same shape and appearance as the tested drug tablets, in the appropriate doses, and containing the same excipients. Participants will initially take one tablet of the medication daily in the morning. The physicians will dispense the drugs in packs of 30 tablets for the entire interval between visits (therapy 26 weeks ± 2 weeks). The patients will receive the medications during visit V1. The drugs will be prepared in identical packages, appropriately sealed, with a number for drug identification.
Trial: NCT02036723
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive bevacizumab at a dose 1.25 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
Trial: NCT02036723
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive ranibizumab at a dose 0.50 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
Trial: NCT00000964
Drug: Ranitidine hydrochloride
RxNorm normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000964
Drug: Foscarnet sodium
RxNorm normalized name: Foscarnet Sodium
DrugBank: Foscarnet (DB00529)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04008628
Drug: Nitrous Oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhalation of a 50%/50% nitrous oxide/oxygen mixture (Kalinox®)
Trial: NCT05363514
Drug: Low Dose Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participant takes Low Dose Naltrexone 4.5mg PO OD for 120 days. Participant will complete a a 4 week titration to target dose of 4.5mg. Week 1-2: 1.5mg PO OD. Week 3-4: 3.0mg PO OD. Week 5-16: 4.5mg PO OD. Participant will be provided with masked capsules in blister packs.
Trial: NCT05363514
Drug: Microcrystalline cellulose
RxNorm normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant takes microcrystalline cellulose 4.5mg PO OD for 120 days. Participant will complete a a 4 week titration to target dose of 4.5mg. Week 1-2: 1.5mg PO OD. Week 3-4: 3.0mg PO OD. Week 5-16: 4.5mg PO OD. Participant will be provided with masked capsules in blister packs.
Trial: NCT04060316
Drug: GLS-1200
RxNorm normalized name: GL-2045
DrugBank: GL-2045 (DB16971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLS-1200 is given as a nasal spray using an atomizer
Trial: NCT05919316
Drug: Nasonex Nasal Spray
RxNorm normalized name: mometasone Metered Dose Nasal Spray [Nasonex]
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mcg/dose, 2 sprays each nostril (morning or evening) once daily for 14 days
Trial: NCT06299852
Drug: Trastuzumab emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SRT for metastatic foci
Trial: NCT06399809
Drug: Fisetin
RxNorm normalized name: FISETIN
DrugBank: Fisetin (DB07795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fisetin is a flavanol, present in strawberries, apples, and persimmons, that destroys senescent cells (i.e. a senolytic therapy). Of three senolytic therapies being tested in clinical trials, fisetin has the best safety profile.
Trial: NCT05009680
Drug: GB1211
RxNorm normalized name: GB1211
DrugBank: GB1211 (DB17499)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day
Trial: NCT05608980
Drug: 0.01% hypochlorous acid
DrugBank: Hypochlorous acid (DB14135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily 0.01% hypochlorous acid topical treatment via ultrasonic atomization for 2 weeks
Trial: NCT04720131
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab was administered 200mg iv every 3 weeks.